NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced,
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Good day and thank you for standing by. Welcome to the LogicMark s Fourth Quarter and 2022 Financial Results and Corporate Update Conference Call.